Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Diamond Therapeutics initiates dosing in first-ever Phase 2a clinical trial evaluating low-dose psilocybin for anxiety

Summary by EIN Presswire
Double-blind, placebo-controlled study explores daily non-psychedelic doses of psilocybin for individuals with Generalized Anxiety Disorder
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

EIN PresswireEIN Presswire

Diamond Therapeutics initiates dosing in first-ever Phase 2a clinical trial evaluating low-dose psilocybin for anxiety

Double-blind, placebo-controlled study explores daily non-psychedelic doses of psilocybin for individuals with Generalized Anxiety Disorder

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

EIN Presswire broke the news in on Wednesday, July 30, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Psychedelics icon

Psychedelics

News
For You
SearchBlindspotLocal